EDAP TMS S.A. — FY 2018 Form 20-F
Reporting period: Year ended December 31, 2018; filed April 12, 2019. This is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under U.S. GAAP and reported in euros.
Business context
EDAP develops, manufactures, sells and services minimally invasive urology devices. Its two divisions are HIFU, including Ablatherm and Focal One prostate-treatment systems, and UDS, including extracorporeal shockwave lithotripsy (ESWL) devices and distributed urology products. UDS was the larger division in 2018. The company’s strategy emphasizes expanding HIFU adoption while generating recurring revenue from treatments, consumables, maintenance and its installed base.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Total revenue | €39.18 million | €35.75 million |
| Gross profit / gross margin | €16.92 million / 43.2% | €14.81 million / 41.5% |
| Operating expenses | €18.23 million | €16.84 million |
| Operating loss | €1.32 million | €2.03 million |
| Net loss / loss per share | €0.34 million / €0.01 | €0.68 million / €0.02 |
| Operating cash flow | €0.18 million | Use of €3.06 million |
| Cash and cash equivalents at year-end | €19.46 million | €20.00 million |
Revenue rose 9.6%. HIFU sales were €11.0 million, up 16.1%; UDS sales were €28.1 million, up 7.3%. Gross margin improved by 1.7 percentage points, while operating expenses grew 8.3%. The net loss narrowed, but the company remained loss-making at the operating and net-income levels. Net income was also affected by €0.80 million of net financial income, €0.54 million of foreign-exchange gains and €0.36 million of income-tax expense. The filing attributes €0.89 million of financial income to warrant-related accounting; all warrants had expired by year-end.
The audited cash flow statement reports positive operating cash flow of €0.175 million in 2018. This differs from risk-factor language elsewhere in the filing describing 2018 operating cash flow as negative. The company reports €1.57 million used in investing activities and €1.18 million generated by financing activities; cash decreased €0.54 million over the year.
At year-end, current assets were €40.38 million and current liabilities €16.81 million. Total assets were €48.74 million and shareholders’ equity €24.96 million. Borrowings comprised €3.68 million of short-term borrowings, €1.83 million of long-term debt and €1.24 million of capital-lease obligations. Cash exceeded these reported borrowings and lease obligations. Contractual operating-lease payments totaled €2.93 million.
Material changes and notable developments
- HIFU device sales increased to €3.6 million, with one Ablatherm and six Focal One units sold, versus two Ablatherm and three Focal One units in 2017. HIFU treatment-driven revenue was nearly flat; maintenance revenue increased to €1.3 million.
- UDS device sales were €15.3 million, slightly above 2017, despite fewer ESWL devices sold (33 versus 40). Consumables, spare parts, distribution products and service revenues supported division growth.
- The company received U.S. FDA 510(k) clearance for Focal One in June 2018 for focal ablation of prostate cancer; Ablatherm Fusion had been cleared in 2017.
- Research and development expense was €4.09 million, net of grants and tax credits. Selling and marketing expense rose to €10.55 million. The filing says the company adopted ASC 606 in 2018; it reports no effect on 2018 revenue or opening equity, while comparative periods remain under the prior revenue standard.
Outlook, risks and contingencies
- Management expects 2019 European R&D spending at approximately 10.7% of revenue and expects selling and marketing expense to continue increasing. No revenue, earnings or cash-flow guidance is provided.
- Management plans continued investment in clinical studies, regulatory approvals—particularly in Japan—reimbursement efforts and HIFU applications beyond prostate cancer. A multicenter endometriosis study and a liver-cancer study were anticipated to begin in 2019.
- HIFU growth depends on regulatory progress, clinical evidence, physician and patient adoption, and reimbursement. U.S. reimbursement for HIFU procedures remained under discussion with private insurers; reimbursement in Europe was limited, with French definitive reimbursement not assured. ESWL is a mature, competitive market.
- The EU Medical Device Regulation transition deadline was May 2020. The company was preparing for the stricter requirements. Other risks include reliance on distributors and some single-source suppliers, manufacturing at one principal French facility, foreign-exchange exposure, and seasonal and lumpy hospital equipment orders.
- Internal controls: Management and KPMG concluded that internal control over financial reporting was not effective at December 31, 2018 because of a material weakness related to implementation of the SAP 4HANA system. The prior-year segregation-of-duties weakness was reported remediated. KPMG issued an adverse opinion on internal-control effectiveness but an unqualified opinion on the 2018 financial statements; management said the weakness did not cause a material misstatement or restatement. Remediation was partly completed and ongoing at filing.
- Warranty obligations, retirement-benefit provisions and conditional government research advances are disclosed. The company reported no material legal proceedings, no outstanding foreign-exchange hedges at year-end and no subsequent events. It paid no dividends and did not anticipate dividends for the foreseeable future.
Most important facts for investors to verify
- Whether HIFU device placements, treatment volumes and recurring treatment-driven revenues grow enough to improve HIFU profitability.
- Progress on U.S. and international reimbursement, regulatory approvals in Japan and China, and MDR readiness before the 2020 transition deadline.
- Whether operating cash flow remains positive as receivables, inventory and commercial investment change; reconcile the filing’s conflicting description of 2018 operating cash flow.
- Completion and independent validation of SAP-related internal-control remediation, given the adverse auditor opinion on controls.
- Debt, lease and conditional-advance obligations, and the impact of currency movements; 41% of sales were denominated in currencies other than the euro while most costs were euro-denominated.